Balcinrenone/Dapagliflozin - AstraZeneca
Latest Information Update: 04 Dec 2024
Price :
$50 *
At a glance
- Originator AstraZeneca
- Class Acetamides; Anti-ischaemics; Antihyperglycaemics; Antivirals; Benzhydryl compounds; Benzoxazines; Cardiovascular therapies; Chlorobenzenes; Fluorinated hydrocarbons; Glucosides; Heart failure therapies; Hepatoprotectants; Obesity therapies; Pyrans; Small molecules; Urologics
- Mechanism of Action Mineralocorticoid receptor modulators; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Heart failure; Renal failure
Most Recent Events
- 21 Oct 2024 AstraZeneca plans a phase I study for an unknown indication in China (PO) (NCT06651021)